4 years ago

NanoSyrinx Raises £6.2M Seed Funding for Targeted Biologic Delivery Platform

  • Coventry-based biotech company NanoSyrinx has secured £6.2 million in seed funding to further develop its novel biologic delivery platform

  • The funding round was co-led by Octopus Ventures and M Ventures, with participation from existing investors BioCity, UKI2S, and new investors IQ Capital and Jonathan Milner

  • NanoSyrinx's technology focuses on engineering protein 'nanosyringes' for targeted drug delivery, aiming to revolutionize disease treatment by directly delivering therapeutics to specific cells

  • The investment will be used to conduct proof-of-concept studies and build a pipeline of programs for future growth.

      • ProblemHealthcare

      "Developing a targeted delivery system to deliver therapeutics directly to diseased cells while minimizing side effects."

      Solution

      "NanoSyrinx's technology engineers protein 'nanosyringes', a cell-selective non-viral peptide and protein delivery system, allowing for targeted delivery of therapeutics to improve efficacy and minimize side effects."

      Covered on